A new addendum to the ICH Good Clinical Practice (GCP) Guideline carries broad implications for sponsors, CROs, and investigators. The guideline, now known as ICH E6 (R2), was drafted in response to advances in technology within clinical trials (e.g. electronic data...
Speaking with FDA
Questions to avoid and the right questions to ask.